Peripheral	peripheral	O	B_disease
neuropathy	neuropathy	O	I_disease
caused	caused	O	O
by	by	O	O
high-dose	high-dose	O	O
cytosine	cytosine	B_chemicals	O
arabinoside	arabinoside	S_chemicals	O
treatment	treatment	O	O
in	in	O	O
a	a	O	O
patient	patient	O	O
with	with	O	O
acute	acute	O	B_disease
myeloid	myeloid	O	B_disease
leukemia	leukemia	O	S_disease
.	.	O	O

The	the	O	O
central	central	O	B_disease
nervous	nervous	O	B_disease
system	system	O	I_disease
toxicity	toxicity	O	I_disease
of	of	O	O
high-dose	high-dose	O	O
cytosine	cytosine	B_chemicals	O
arabinoside	arabinoside	S_chemicals	O
is	is	O	O
well	well	O	O
recognized	recognized	O	O
,	,	O	O
but	but	O	O
the	the	O	O
toxicity	toxicity	O	O
of	of	O	O
cytosine	cytosine	B_chemicals	O
arabinoside	arabinoside	S_chemicals	O
in	in	O	O
the	the	O	O
peripheral	peripheral	O	O
nervous	nervous	O	B_disease
system	system	O	I_disease
has	has	O	O
been	been	O	O
infrequently	infrequently	O	O
reported	reported	O	O
.	.	O	O

A	a	O	O
49-year-old	49-year-old	O	O
Japanese	japanese	O	O
man	man	O	O
was	was	O	O
diagnosed	diagnosed	O	O
with	with	O	O
acute	acute	O	B_disease
myeloid	myeloid	O	B_disease
leukemia	leukemia	O	S_disease
.	.	O	O

After	after	O	O
he	he	O	O
achieved	achieved	O	O
complete	complete	O	O
remission	remission	O	O
,	,	O	O
he	he	O	O
received	received	O	O
high-dose	high-dose	O	O
cytosine	cytosine	B_chemicals	O
arabinoside	arabinoside	S_chemicals	O
treatment	treatment	O	O
(	(	B_chemicals	O
2	2	I_chemicals	O
g/m2	g/m2	O	O
twice	twice	O	O
a	a	O	O
day	day	O	O
for	for	O	O
5	5	O	O
days	days	O	O
;	;	O	O
total	total	O	O
,	,	O	O
20	20	O	O
g/m2	g/m2	O	O
)	)	O	O
as	as	O	O
consolidation	consolidation	O	O
therapy	therapy	O	O
.	.	O	O

The	the	O	O
first	first	O	O
course	course	O	O
of	of	O	O
high-dose	high-dose	O	O
cytosine	cytosine	B_chemicals	O
arabinoside	arabinoside	S_chemicals	O
resulted	resulted	O	O
in	in	O	O
no	no	O	O
unusual	unusual	O	O
symptoms	symptoms	O	O
,	,	O	O
but	but	O	O
on	on	O	O
day	day	O	O
21	21	O	O
of	of	O	O
the	the	O	O
second	second	O	O
course	course	O	O
of	of	O	O
treatment	treatment	O	O
,	,	O	O
the	the	O	O
patient	patient	O	O
complained	complained	O	O
of	of	O	O
numbness	numbness	O	S_disease
in	in	O	O
his	his	S_chemicals	O
right	right	O	O
foot	foot	O	O
.	.	O	O

Electromyogram	electromyogram	O	O
and	and	O	O
nerve-conduction	nerve-conduction	O	O
studies	studies	O	O
showed	showed	O	O
peripheral	peripheral	O	B_disease
neuropathy	neuropathy	O	I_disease
in	in	O	O
both	both	O	O
peroneal	peroneal	O	O
nerves	nerves	O	O
.	.	O	O

This	this	O	O
neuropathy	neuropathy	O	O
was	was	O	O
gradually	gradually	O	O
resolving	resolving	O	O
;	;	O	O
however	however	O	O
,	,	O	O
after	after	O	O
the	the	O	O
patient	patient	O	O
received	received	O	O
allogeneic	allogeneic	O	O
bone	bone	O	B_disease
marrow	marrow	O	I_disease
transplantation	transplantation	O	O
,	,	O	O
the	the	O	O
symptoms	symptoms	O	O
worsened	worsened	O	O
,	,	O	O
with	with	O	O
the	the	O	O
development	development	O	O
of	of	O	O
graft-versus-host	graft-versus-host	O	B_disease
disease	disease	O	S_disease
,	,	O	O
and	and	O	O
the	the	O	O
symptoms	symptoms	O	O
subsequently	subsequently	O	O
responded	responded	O	O
to	to	O	O
methylprednisolone	methylprednisolone	S_chemicals	O
.	.	O	O

Although	although	O	O
the	the	O	O
mechanisms	mechanisms	O	O
of	of	O	O
peripheral	peripheral	O	B_disease
neuropathy	neuropathy	O	I_disease
are	are	O	O
still	still	O	O
unclear	unclear	O	O
,	,	O	O
high-dose	high-dose	O	O
cytosine	cytosine	B_chemicals	O
arabinoside	arabinoside	S_chemicals	O
is	is	O	O
a	a	O	O
therapy	therapy	O	O
that	that	O	O
is	is	O	O
potentially	potentially	O	O
toxic	toxic	O	O
to	to	O	O
the	the	O	O
peripheral	peripheral	O	O
nervous	nervous	O	B_disease
system	system	O	I_disease
,	,	O	O
and	and	O	O
auto/alloimmunity	auto/alloimmunity	O	O
may	may	O	O
play	play	O	O
an	an	O	O
important	important	O	O
role	role	O	O
in	in	O	O
these	these	O	O
mechanisms	mechanisms	O	O
.	.	O	O

